checkpoint inhibitor

Oncolytic viruses can help glioblastoma respond to immunotherapy.

New research may make immunotherapy possible for hard-to-treat brain tumors.

The Transcreener dAMP Exonuclease Assay reliably locates compounds that antagonize TREX1.

A career-altering experience as a cancer patient motivated one researcher to design more potent immunotherapies.

At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.

Researchers describe ways to study how cancer cells evade therapies that harness the immune system.

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.

Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.

The immunologists, honored with the 2018 award in Physiology or Medicine, pioneered immunotherapy, which harnesses the body’s immune system to fight cancer.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.

Women with metastatic cancer who were treated with a checkpoint inhibitor had a smaller benefit than did men.